We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
SpectraScience Inc (CE) | USOTC:SCIE | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 01:00:00 |
"The granting of this new patent is indicative of our commitment to improving and expanding our already large intellectual property portfolio in this space. The diagnosis and detection of cancer, non-invasively using light, is becoming an increasingly more important tool for oncologists," says Michael Oliver, President & CEO of SpectraScience. Mr. Oliver continued, "We will continue to emphasize developing new intellectual property to support our current and future non-invasive, real-time cancer diagnostic systems."
SpectraScience currently holds thirty-three U.S. Patents relating to optical diagnostic systems and forceps, spectral analysis and imaging techniques. In addition, the company holds approximately twenty-five active foreign counterpart patents, primarily in the European Union and Japan.
About SpectraScience, Inc.
SpectraScience is a San Diego-based medical device company that designs, develops, manufactures and markets light-based analysis systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically diagnose tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.
Contact: SpectraScience, Inc. Jim Dorst Chief Financial Officer (858) 405-9933
1 Year SpectraScience (CE) Chart |
1 Month SpectraScience (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions